Enhancing Diabetes Care: Exposome &Amp; Sensors
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT06989008
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences — OTHERThis is a single group observational study with no interventions.
Study Details
The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.
Key Dates
- Start date
- Mar 25, 2025
- Status verified
- May 2025
- Primary completion
- Jan 1, 2026
- Completion
- Jan 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
Arms
- Arm: Type 2 DiabetesThe study will include adults with Type 2 Diabetes living in an urban setting characterized by poor health outcomes.
Primary Outcome Measure
The primary outcome is to collect and analyze continuous interstitial glucose measurements in 20 individuals with type 2 diabetes over a period of 20 days using a DEXCOM G7 continuous glucose monitor (CGM). [ Time Frame: 20 days ]
Central Contacts
- Laurie Quinn, PhD312 771 6497
- Sulaimon Balogun, PhD Student773-971-0503
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Illinois - Chicago | Chicago | Illinois | 60612 | |
| University of Illinois College of Nursing | Chicago | Illinois | 60612 | Laurie Quinn, PhD RN (SUB_INVESTIGATOR) |
Find similar trials in Chicago, IL
By condition
By specialty
Related Studies
- My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 DiabetesRecruiting · University of Illinois at Chicago · Chicago, Illinois
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesRecruiting · Endogenex, Inc. · Birmingham, Alabama
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)PHASE2 · Recruiting · Sparrow Pharmaceuticals · Chandler, Arizona